Tags

Type your tag names separated by a space and hit enter

Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention.
Am J Cardiol 2017; 120(7):1122-1128AJ

Abstract

Diabetes mellitus (DM), a modern-day epidemic, is a significant risk factor for cardiovascular disease. It is believed that statins elevate the risk of incident DM. Multiple trials were suggestive of the hyperglycemic effect of long-term statin use. This has prompted the Food and Drug Administration to include the risk of DM in the product label of statins. New-onset DM with statin use is biologically plausible and can be explained based on the multiple pathways in glucose metabolism affected by statins. Most pivotal clinical trials on statins were not powered to adequately assess the risk of incident DM with statin use, and the results from multiple meta-analyses are mixed. Currently, the US Preventive Services Task Force recommend the use of statins for primary prevention in patients with at least 1 cardiovascular risk factor and a 10-year risk of >7.5%. With the new American College of Cardiology/American Heart Association guidelines, the number of patients eligible for statin therapy has increased exponentially, which also calls for caution and increased vigilance in prescribing physicians regarding the controversies surrounding statin use. This article aims to highlight the existing data on statin use for primary prevention in diabetics and nondiabetics and the association of statins use with new-onset DM and its postulated mechanisms.

Authors+Show Affiliations

Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.Division of Cardiology, University of Rome Tor Vergata, Rome, Italy.Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, Arkansas. Electronic address: MehtaJL@uams.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28797470

Citation

Rochlani, Yogita, et al. "Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention." The American Journal of Cardiology, vol. 120, no. 7, 2017, pp. 1122-1128.
Rochlani Y, Kattoor AJ, Pothineni NV, et al. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol. 2017;120(7):1122-1128.
Rochlani, Y., Kattoor, A. J., Pothineni, N. V., Palagiri, R. D. R., Romeo, F., & Mehta, J. L. (2017). Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. The American Journal of Cardiology, 120(7), pp. 1122-1128. doi:10.1016/j.amjcard.2017.06.054.
Rochlani Y, et al. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol. 2017 Oct 1;120(7):1122-1128. PubMed PMID: 28797470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. AU - Rochlani,Yogita, AU - Kattoor,Ajoe John, AU - Pothineni,Naga Venkata, AU - Palagiri,Raga Deepak Reddy, AU - Romeo,Francesco, AU - Mehta,Jawahar L, Y1 - 2017/07/14/ PY - 2017/04/05/received PY - 2017/06/11/revised PY - 2017/06/29/accepted PY - 2017/8/12/pubmed PY - 2017/9/15/medline PY - 2017/8/12/entrez SP - 1122 EP - 1128 JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 120 IS - 7 N2 - Diabetes mellitus (DM), a modern-day epidemic, is a significant risk factor for cardiovascular disease. It is believed that statins elevate the risk of incident DM. Multiple trials were suggestive of the hyperglycemic effect of long-term statin use. This has prompted the Food and Drug Administration to include the risk of DM in the product label of statins. New-onset DM with statin use is biologically plausible and can be explained based on the multiple pathways in glucose metabolism affected by statins. Most pivotal clinical trials on statins were not powered to adequately assess the risk of incident DM with statin use, and the results from multiple meta-analyses are mixed. Currently, the US Preventive Services Task Force recommend the use of statins for primary prevention in patients with at least 1 cardiovascular risk factor and a 10-year risk of >7.5%. With the new American College of Cardiology/American Heart Association guidelines, the number of patients eligible for statin therapy has increased exponentially, which also calls for caution and increased vigilance in prescribing physicians regarding the controversies surrounding statin use. This article aims to highlight the existing data on statin use for primary prevention in diabetics and nondiabetics and the association of statins use with new-onset DM and its postulated mechanisms. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/28797470/Balancing_Primary_Prevention_and_Statin_Induced_Diabetes_Mellitus_Prevention_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(17)31116-5 DB - PRIME DP - Unbound Medicine ER -